Integra Lifesciences Holdings (IART) Other Operating Expenses (2009 - 2026)

Integra Lifesciences Holdings has reported Other Operating Expenses for 17 years, with the latest figure at $202.8 million in Q2 2026.

• Quarterly Other Operating Expenses fell 71.89% year-over-year to $202.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $798.1 million (down 38.37% YoY) and the FY2025 annual result came in at $1.3 billion, changed N/A from the prior year.
• Other Operating Expenses grew to $202.8 million in Q2 2026 per IART's latest filing, from $178.7 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $721.4 million in Q2 2025 and troughed at $644000.0 in Q3 2022.
• A 5-year average of $214.6 million and a median of $191.9 million in 2025 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2022 and 2026: Other Operating Expenses surged 380.0% in 2022, then slumped 71.89% in 2026.
• Over 5 years, Other Operating Expenses stood at $644000.0 in 2022, then jumped by 27425.93% to $177.3 million in 2023, then grew by 11.29% to $197.3 million in 2024, then climbed by 10.41% to $217.8 million in 2025, then declined by 6.9% to $202.8 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $202.8 million, $178.7 million, and $217.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.